(Q30240201)

12 June 2017

1 reference

title

Crohn's disease (English)

1 reference

12 June 2017

0 references

Laurent Peyrin-Biroulet

series ordinal

4

object named as

Laurent Peyrin-Biroulet

1 reference

12 June 2017

Jean-Frédéric Colombel

series ordinal

3

object named as

Jean-Frédéric Colombel

1 reference

12 June 2017

Joana Torres

1

1 reference

12 June 2017

Saurabh Mehandru

series ordinal

2

1 reference

12 June 2017

language of work or name

English

0 references

publication date

30 November 2016

1 reference

12 June 2017

1 reference

12 June 2017

volume

389

1 reference

12 June 2017

issue

10080

1 reference

12 June 2017

page(s)

1741-1755

1 reference

Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort

12 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

The natural history of adult Crohn's disease in population-based cohorts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Inflammatory bowel disease in immigrants to Canada and their children: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Familial risk of inflammatory bowel disease: a population-based cohort study 1977-2011.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Epidemiology and risk factors for IBD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Genetics of Inflammatory Bowel Diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Genetics and phenotypes in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Cesarean Section Delivery Is Not a Risk Factor for Development of Inflammatory Bowel Disease: A Population-based Analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Smoking and inflammatory bowel disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Statins Associated With Decreased Risk of New Onset Inflammatory Bowel Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Long-term intake of dietary fat and risk of ulcerative colitis and Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

The microbiome in inflammatory bowel disease: current status and the future ahead

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Crohn's disease-associated adherent-invasive E. coli are selectively favoured by impaired autophagy to replicate intracellularly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Disease-specific alterations in the enteric virome in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Fungal microbiota dysbiosis in IBD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

The antibacterial lectin RegIIIgamma promotes the spatial segregation of microbiota and host in the intestine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Mucin function in inflammatory bowel disease: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Autophagy in immunity and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Intestinal epithelial autophagy is essential for host defense against invasive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Characteristics of Intestinal Dendritic Cells in Inflammatory Bowel Diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Macrophages in intestinal homeostasis and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Group 3 innate lymphoid cells inhibit T-cell-mediated intestinal inflammation through aryl hydrocarbon receptor signaling and regulation of microflora.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Paneth cells and innate mucosal immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

CD4+ T-cell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Immune Responses to Intestinal Microbes in Inflammatory Bowel Diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Intestinal homeostasis and its breakdown in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

The B-cell system in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Homing imprinting and immunomodulation in the gut: role of dendritic cells and retinoids

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

The spectrum of perianal Crohn's disease in a population-based cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

European consensus on the histopathology of inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Differentiation of Crohn's disease from intestinal tuberculosis by clinical and CT enterographic models.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Clinical Features, Diagnosis, and Treatment Strategies of Gastrointestinal Diaphragm Disease Associated with Nonsteroidal Anti-Inflammatory Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Increased immune reactivity predicts aggressive complicating Crohn's disease in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Correspondence: fecal calprotectin and cut-off levels in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

European evidence based consensus for endoscopy in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Inflammatory bowel disease biopsies: updated British Society of Gastroenterology reporting guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

IOIBD technical review on endoscopic indices for Crohn's disease clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Development of an index to define overall disease severity in IBD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Development of the Crohn's disease digestive damage score, the Lémann score

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Perianal Fistula With and Without Abscess: Assessment of Fistula Activity Using Diffusion-Weighted Magnetic Resonance Imaging.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Factors affecting outcomes in Crohn's disease over 15 years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Short Bowel Syndrome and Intestinal Failure in Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Review article: the natural history of postoperative Crohn's disease recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Clinical risk factors for complicated disease: how reliable are they?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Preventing postoperative recurrence in Crohn's disease: what does the future hold?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Predicting complicated Crohn's disease and surgery: phenotypes, genetics, serology and psychological characteristics of a population-based cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Biologic agents for IBD: practical insights

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Budesonide for induction of remission in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Budesonide for maintenance of remission in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Traditional corticosteroids for induction of remission in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Enteral nutritional therapy for induction of remission in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Methotrexate for induction of remission in refractory Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Methotrexate for maintenance of remission in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Diagnosis of liver fibrosis by transient elastography (FibroScan) and non-invasive methods in Crohn's disease patients treated with methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Infliximab maintenance therapy for fistulizing Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Adalimumab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Infliximab, azathioprine, or combination therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Systematic review: Monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Vedolizumab as induction and maintenance therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Ustekinumab induction and maintenance therapy in refractory Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohnʼs Disease Refractory to Anti-TFNα

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Clinical Practice Guideline for the Surgical Management of Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Review article: optimal preparation for surgery in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Inflammatory Bowel Disease Increases Risk of Adverse Pregnancy Outcomes: A Meta-Analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Pregnancy and the Patient with Inflammatory Bowel Disease: Fertility, Treatment, Delivery, and Complications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Toward a personalized medicine approach to the management of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Association between TNF-α (-308 A/G, -238 A/G, -857 C/T) polymorphisms and responsiveness to TNF-α blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931711-1

7 January 2021

10.1016/S0140-6736(16)31711-1

Identifiers

DOI

1 reference

12 June 2017

1 reference